These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8877700)

  • 1. A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists.
    Hariprasad V; Kulkarni VM
    J Comput Aided Mol Des; 1996 Aug; 10(4):284-92. PubMed ID: 8877700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional quantitative structure-activity relationship (QSAR) and receptor mapping of cytochrome P-450(14 alpha DM) inhibiting azole antifungal agents.
    Talele TT; Kulkarni VM
    J Chem Inf Comput Sci; 1999; 39(2):204-10. PubMed ID: 10192939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
    Shenderovich MD; Liao S; Qian X; Hruby VJ
    Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a common 3D pharmacophore for delta-opioid recognition from peptides and non-peptides using a novel computer program.
    Huang P; Kim S; Loew G
    J Comput Aided Mol Des; 1997 Jan; 11(1):21-8. PubMed ID: 9139108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 3D-QSAR models for 5-lipoxygenase antagonists: chalcones.
    Arockia Babu M; Shakya N; Prathipati P; Kaskhedikar SG; Saxena AK
    Bioorg Med Chem; 2002 Dec; 10(12):4035-41. PubMed ID: 12413856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update.
    Moro S; Deflorian F; Bacilieri M; Spalluto G
    Curr Med Chem; 2006; 13(6):639-45. PubMed ID: 16529556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of recognition of ligands binding to benzodiazepine receptor/GABA(A) receptors initiating sedation.
    Harris DL; DeLorey TM; He X; Cook JM; Loew GH
    Eur J Pharmacol; 2000 Aug; 401(3):271-87. PubMed ID: 10936485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
    Peng T; Pei J; Zhou J
    J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series.
    Palomer A; Pascual J; Cabré F; García ML; Mauleón D
    J Med Chem; 2000 Feb; 43(3):392-400. PubMed ID: 10669566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.
    Dixon SL; Smondyrev AM; Knoll EH; Rao SN; Shaw DE; Friesner RA
    J Comput Aided Mol Des; 2006; 20(10-11):647-71. PubMed ID: 17124629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists.
    Belvisi L; Bravi G; Catalano G; Mabilia M; Salimbeni A; Scolastico C
    J Comput Aided Mol Des; 1996 Dec; 10(6):567-82. PubMed ID: 9007690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3D QSAR approach to the search for geometrical similarity in a series of nonpeptide angiotensin II receptor antagonists.
    Belvisi L; Bravi G; Scolastico C; Vulpetti A; Salimbeni A; Todeschini R
    J Comput Aided Mol Des; 1994 Apr; 8(2):211-20. PubMed ID: 8064335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
    Gund TM; Floyd J; Jung D
    J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU; Bembenek SD; Szalma S
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
    Aher RB; Roy K
    Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.
    Prendergast K; Adams K; Greenlee WJ; Nachbar RB; Patchett AA; Underwood DJ
    J Comput Aided Mol Des; 1994 Oct; 8(5):491-512. PubMed ID: 7876897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.